These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7697680

  • 1. Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy.
    Hotta N, Sugimura K, Tsuchida I, Sano T, Koh N, Matsumae H, Sakamoto N.
    Clin Ther; 1994; 16(6):1007-15. PubMed ID: 7697680
    [Abstract] [Full Text] [Related]

  • 2. Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes.
    Fujita Y, Fukushima M, Suzuki H, Taniguchi A, Nakai Y, Kuroe A, Yasuda K, Hosokawa M, Yamada Y, Inagaki N, Seino Y.
    Diabetes Res Clin Pract; 2008 Apr; 80(1):e16-9. PubMed ID: 18262304
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
    Akahori H, Takamura T, Hayakawa T, Ando H, Yamashita H, Kobayashi K.
    Diabetes Res Clin Pract; 2004 Jun; 64(3):153-9. PubMed ID: 15126001
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening.
    Kamei N, Yamane K, Nakanishi S, Yamashita Y, Tamura T, Ohshita K, Watanabe H, Fujikawa R, Okubo M, Kohno N.
    J Diabetes Complications; 2005 Jun; 19(1):47-53. PubMed ID: 15642490
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
    Bastyr EJ, Price KL, Bril V, MBBQ Study Group.
    Clin Ther; 2005 Aug; 27(8):1278-94. PubMed ID: 16199253
    [Abstract] [Full Text] [Related]

  • 7. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R.
    Biomed Pharmacother; 1995 Aug; 49(6):269-77. PubMed ID: 7579007
    [Abstract] [Full Text] [Related]

  • 8. [Perception of vibration. Normal findings and methodologic aspects].
    Claus D, Carvalho VP, Neundörfer B, Blaise JF.
    Nervenarzt; 1988 Mar; 59(3):138-42. PubMed ID: 3374714
    [Abstract] [Full Text] [Related]

  • 9. Reproducibility of different methods for diagnosing and monitoring diabetic neuropathy.
    Nasseri K, Strijers RL, Dekhuijzen LS, Buster M, Bertelsmann FW.
    Electromyogr Clin Neurophysiol; 1998 Mar; 38(5):295-9. PubMed ID: 9741007
    [Abstract] [Full Text] [Related]

  • 10. The level of small nerve fiber dysfunction does not predict pain in diabetic Neuropathy: a study using quantitative sensory testing.
    Sorensen L, Molyneaux L, Yue DK.
    Clin J Pain; 2006 Mar; 22(3):261-5. PubMed ID: 16514326
    [Abstract] [Full Text] [Related]

  • 11. Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.
    Hotta N, Yasuda K, Sumita Y, Sano T, Kakuta H, Nagashima M, Hayashi Y, Yamamoto M, Wakao T, Okuyama M, Kobayashi M, Mori K.
    Clin Drug Investig; 2004 Mar; 24(11):671-80. PubMed ID: 17523730
    [Abstract] [Full Text] [Related]

  • 12. The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy.
    Tawata M, Kurihara A, Nitta K, Iwase E, Gan N, Onaya T.
    Diabetes Res Clin Pract; 1994 Dec 16; 26(2):121-8. PubMed ID: 7705193
    [Abstract] [Full Text] [Related]

  • 13. Comparison of clinical examination, current and vibratory perception threshold in diabetic polyneuropathy.
    Tack CJ, Netten PM, Scheepers MH, Meijer JW, Smits P, Lutterman J.
    Neth J Med; 1994 Feb 16; 44(2):41-9. PubMed ID: 8208323
    [Abstract] [Full Text] [Related]

  • 14. Reproducibility of vibratory perception thresholds in patients with diabetic neuropathy.
    Bertelsmann FW, Heimans JJ, van Rooy JC, Heine RJ, van der Veen EA.
    Diabetes Res; 1986 Nov 16; 3(9):463-6. PubMed ID: 3829585
    [Abstract] [Full Text] [Related]

  • 15. [Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs].
    Bregovskiĭ VB, Posokhina OV, Karpova IA.
    Ter Arkh; 2005 Nov 16; 77(10):15-9. PubMed ID: 16320678
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Diabetic neuropathy in patients with "latent autoimmune diabetes of the adults" (LADA) compared with patients with type 1 and type 2 diabetes.
    Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F.
    J Neurol; 2003 Jun 16; 250(6):682-7. PubMed ID: 12796829
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effects of Vibro-medical insole on vibrotactile sensation in diabetic patients with mild-to-moderate peripheral neuropathy.
    Bagherzadeh Cham M, Mohseni-Bandpei MA, Bahramizadeh M, Kalbasi S, Biglarian A.
    Neurol Sci; 2018 Jun 16; 39(6):1079-1084. PubMed ID: 29594830
    [Abstract] [Full Text] [Related]

  • 20. Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome.
    Dornonville de la Cour C, Jakobsen J.
    Neurology; 2005 Jan 25; 64(2):246-53. PubMed ID: 15668421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.